Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $11.67 Average Price Target from Analysts

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) has earned an average rating of “Moderate Buy” from the five research firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $11.6667.

Separately, Weiss Ratings raised Acrivon Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th.

Acrivon Therapeutics Price Performance

ACRV opened at $1.60 on Friday. The company has a market cap of $68.48 million, a PE ratio of -0.80 and a beta of 1.82. Acrivon Therapeutics has a twelve month low of $1.20 and a twelve month high of $3.56. The company has a 50-day moving average price of $1.68 and a 200 day moving average price of $1.72.

Acrivon Therapeutics (NASDAQ:ACRV) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.49) EPS for the quarter, hitting the consensus estimate of ($0.49). As a group, sell-side analysts expect that Acrivon Therapeutics will post -1.92 earnings per share for the current year.

Institutional Investors Weigh In On Acrivon Therapeutics

A number of hedge funds have recently modified their holdings of the business. Invesco Ltd. purchased a new position in shares of Acrivon Therapeutics in the first quarter worth about $72,000. XTX Topco Ltd purchased a new stake in Acrivon Therapeutics during the 2nd quarter valued at about $126,000. Jane Street Group LLC acquired a new stake in Acrivon Therapeutics in the 2nd quarter valued at about $371,000. UBS Group AG raised its holdings in Acrivon Therapeutics by 150,057.8% in the 3rd quarter. UBS Group AG now owns 683,218 shares of the company’s stock valued at $1,237,000 after acquiring an additional 682,763 shares during the last quarter. Finally, Two Sigma Investments LP lifted its stake in Acrivon Therapeutics by 76.2% in the 3rd quarter. Two Sigma Investments LP now owns 319,205 shares of the company’s stock worth $578,000 after purchasing an additional 138,033 shares in the last quarter. 71.62% of the stock is currently owned by institutional investors and hedge funds.

About Acrivon Therapeutics

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.